{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:33:19Z","timestamp":1768969999577,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.107967","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T04:20:10Z","timestamp":1626582010000},"page":"107967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Consider drug induced pemphigus before establishing a diagnosis of paraneoplastic pemphigus (PNP)"],"prefix":"10.1016","volume":"99","author":[{"given":"Thomas N.","family":"Helm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F.","family":"Helm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus F.","family":"Helm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107967_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107299","article-title":"Drug-induced pemphigus: A systematic review of 170 patients","volume":"92","author":"Ghaedi","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107967_b0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.autrev.2018.04.008","article-title":"Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus","volume":"17","author":"Amber","year":"2018","journal-title":"Autoimmun Rev."},{"issue":"4","key":"10.1016\/j.intimp.2021.107967_b0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0190-9622(92)70220-A","article-title":"Paraneoplastic pemphigus: a report of three cases including one long-term survivor","volume":"27","author":"Camisa","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107967_b0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archderm.1993.01680280071014","article-title":"Paraneoplastic Pemphigus Is a Distinct Neoplasia-Induced Autoimmune Disease","volume":"129","author":"Camisa","year":"1993","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.intimp.2021.107967_b0025","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2021.107967_b0030","unstructured":"https:\/\/www.statista.com\/statistics\/184405\/percentage-of-population-with-cancer-in-the-us\/ (accessed 6\/30\/21)."},{"key":"10.1016\/j.intimp.2021.107967_b0035","first-page":"1","article-title":"Paraneoplastic pemphigus: Revised diagnostic criteria based on literature analysis","author":"Svoboda","year":"2021","journal-title":"J Cutan Pathol."},{"key":"10.1016\/j.intimp.2021.107967_b0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.freeradbiomed.2017.04.001","article-title":"D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress","volume":"108","author":"Sciegienka","year":"2017","journal-title":"Free Radic Biol Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.107967_b0045","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/1346-8138.14601","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume":"46","author":"Ito","year":"2019","journal-title":"J Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107967_b0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/archderm.1990.01670340071011","article-title":"Ionizing Radiation-Induced Pemphigus: Case Presentations and Literature Review","volume":"126","author":"Low","year":"1990","journal-title":"Arch Dermatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:13:28Z","timestamp":1730837608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921006032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":10,"alternative-id":["S1567576921006032"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107967","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consider drug induced pemphigus before establishing a diagnosis of paraneoplastic pemphigus (PNP)","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107967"}}